Posted by Michael Wonder on 15 Sep 2016
Ticagrelor for prevention after myocardial infarction: added benefit called into question by data subsequently submitted
15 September 2016 - Greater consistency and certainty of conclusions of the results regarding harmful aspects.
The drug ticagrelor has been approved since February 2016 for adults who had a myocardial infarction a year or more ago and are at a high risk of a new myocardial infarction or stroke. Ticagrelor is used together with low-dose acetylsalicylic acid (aspirin). In its dossier assessment published in early July 2016, the German IQWiG determined an indication of a minor added benefit of ticagrelor in comparison with the administration of ASA alone.
On the inclusion of additional analyses that the drug manufacturer provided in the commenting procedure conducted by the Federal Joint Committee (G-BA), the Institute now came to a different conclusion, however: An added benefit is not proven because positive effects are called into question by negative effects.
